Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersCalendar 

Zogenix Inc. : Trading of Zogenix Common Stock Halted

12/07/2012 | 08:00am US/Eastern

FDA Advisory Committee Reviewing Zohydro™ ER New Drug Application

Zogenix to Host Conference Call at 6:30 pm ET Today

SAN DIEGO, Dec. 7, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced that NASDAQ halted trading of the company's common stock on December 7, 2012. The U.S. Food and Drug Administration's (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) is meeting today to review the Company's New Drug Application (NDA) for Zohydro™ ER (hydrocodone bitartrate extended-release capsules).

Conference Call & Webcast

Zogenix will host a conference call to discuss the outcome of the AADPAC meeting today, Friday, December 7, 2012 at 6:30 p.m. ET (3:30 p.m. PT). To participate, please dial (800) 299-9086 (U.S.) or (617) 786-2903 (International); participant passcode: 21970283. To access the live webcast please visit the Zogenix Investor Relations website at http://ir.zogenix.com.  

The conference call will be hosted by Chief Executive Officer Roger L. Hawley and President and Chief Operating Officer Stephen J. Farr, Ph.D.

A replay of the conference call will be available beginning December 7, 2012 at 8:30 p.m. ET (5:30 p.m. PT) until December 14, 2012, by dialing (888) 286-8010 (U.S.) or (617) 801-6888 (International); passcode: 27116437. A replay of the webcast will also be accessible on the Investor Relations website for one month, through January 10, 2013.

About Anesthetic and Analgesic Drug Products Advisory Committee

The AADPAC reviews and evaluates available data concerning the safety and effectiveness of marketed and investigational human anesthetic and analgesic drug products and makes appropriate recommendations to the Commissioner of Food and Drugs. The AADPAC provides FDA with independent expert advice and recommendations, however, the final decision regarding approval is made by FDA.

About Zogenix

Zogenix, Inc., with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, ZohydroTM ER (hydrocodone bitartrate) is an oral, novel extended-release formulation of various strengths of hydrocodone without acetaminophen intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. Zogenix's second DosePro investigational product candidate, ReldayTM, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia. In May 2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER and an Investigational New Drug Application for Relday. The FDA assigned a PDUFA target action date of March 1, 2013 for the Zohydro ER NDA.

For additional information, please visit www.zogenix.com.

SUMAVEL ®, DosePro ®, ReldayTM and ZohydroTM ER are trademarks of Zogenix, Inc.

CONTACT: INVESTORS:
         Zack Kubow | The Ruth Group
         646.536.7020 | zkubow@theruthgroup.com

         MEDIA:
         Emily Poe | WCG
         212.301.7183 | epoe@wcgworld.com
Zogenix
distributed by
React to this article
Latest news
Date Title
02:33a AIR LIQUIDE : Announces the Acquisition of a Service Leader Specialized in Temperature-Controlled Logistics for the Pharmaceutical Industry
02:32a ASAHI KASEI : chief to resign over piling data falsification
02:32a MCDONALD JAPAN : logs 2nd straight year of net loss in 2015
02:32a WPP : *jpmorgan raises wpp price target to 1770 pence - 'overweight'
02:32a ISS A/S : wins large integrated facility services contract with Rolls-Royce in Asia and Americas
02:32a ADB ASIAN DEVELOPMENT BANK : President Nakao Signs Partnership Framework with Australia
02:32a MITSUBISHI HEAVY : "MHI REPORT 2015" Receives Second Prize in "18th Nikkei Annual Report Awards"
02:32a SWATCH : and Safilo Group announce five-year collaboration agreement
02:31a VIKING SUPPLY SHIPS : Change of financial calendar for Viking Supply Ships AB.
02:31a NOBINA : appoints Anna Jonasson as Head of Central Operational Resources
Latest news
Advertisement
Hot News 
MARIANA RESOURCES : Highest Grade Gold‐Copper Intercept to Date for Hot Maden
BRIXMOR PROPERTY : Goldberg Law PC Announces an Ongoing Investigation of Claims against Brixmor Property Group Inc. and Strongly Encourages Investors to Contact the Firm
BIOCRYST PHARMACEUTICALS : stock price falls 71 percent following recent trial results
FIRST DATA : Merchant Link Achieves EMV Certification with Chase Paymentech and First Data on the Verifone VX Device Family
REC SILICON ASA : Washington closure won't affect Butte, spokesman says
Most Read News
02/08 CLARIZEN : Appoints Boaz Chalamish as Chief Executive Officer
02/08 DAIRY AUSTRALIA : Cream of graduates begin coveted Dairy Manufacturing Scholarship
02/09 PLATINUM CAPITAL : Notification of dividend / distribution
02/08 ABARES AUSTRALIAN BUREAU OF AGRICULTURAL AND RES : Mixed news in latest crop report​
02/08 JUMPSTART REPORTS : Audi, Acura, Honda, Hyundai, and Jeep See Highest Share of Traffic Throughout Super Bowl 50
Most recommended articles
02:29a Sanofi pledges stable 2016 earnings despite fourth-quarter decline
02:19a German industrial output plunges in Dec, exports also drop
02:11a Nikkei posts biggest drop in three years as global growth fears hit banks
02:10aDJMICHAEL WOLF : Swedbank Replaces Chief Executive Michael Wolf
01:45aDJSyria Forces Squeeze Rebels